Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer

Evaluate the efficacy and safety of Trilaciclib for myeloprotection prior to chemotherapy in advanced cholangiocarcinoma or pancreatic cancer.

Participants needed: 96
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: The Second Affiliated Hospital of Shandong First Medical UniversityUpdated: Sep 8, 2025
Eligibility criteria

Age >18 years, male or female. [+5]

History of myeloid leukemia, myelodysplastic syndrome, or concurrent sickle cell... [+7]

Read more
Status: Not yet recruiting

A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma

To evaluate the efficacy of Iparomlimab and Tuvonralimab in combination with Lenvatinib and TACE for advanced hepatocellular carcinoma by assessing Progression-Free Survival (PFS).

Participants needed: 41
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: The Second Affiliated Hospital of Shandong First Medical UniversityUpdated: Sep 2, 2025
Eligibility criteria

Confirmed diagnosis of hepatocellular carcinoma (HCC), aged > 18 years. No prior... [+10]

Concomitant hepatic encephalopathy. [+8]

Read more
Status: Not yet recruiting

The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors

Evaluate the progression-free survival (PFS) of benmelstobart combined with gemcitabine and cisplatin in first-line patients with advanced cholangiocarcinoma, and the progression-free survival (PFS) of benmelstobart combined with anlotinib in second-line patients with advanced cholangiocarcinoma.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: The Second Affiliated Hospital of Shandong First Medical UniversityUpdated: Aug 7, 2025
Eligibility criteria

Hemoglobin (HB) ≥90 g/L (without blood transfusion within 14 days prior). [+6]

Read more
Status: Not yet recruiting

The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer

To evaluate the efficacy and safety of TAS-102 combined with bevacizumab as first-line therapy in patients with advanced colorectal cancer who could not tolerate or did not receive combined chemotherapy

Participants needed: 50
Trial details
Phase: Phase 2Age: 18-85Biological sex: AllType: InterventionalSponsor: The Second Affiliated Hospital of Shandong First Medical UniversityUpdated: Oct 23, 2023Locations: 1
Eligibility criteria

Age ≥18 years [+9]

the presence of other active malignancies at the same time, excluding those that... [+12]

Read more